Eli Lil­ly dish­es out first mile­stone pay­ment for Alzheimer's deal; ADC Ther­a­peu­tics, Viela Bio set terms for IPO

→ With oth­ers shy­ing away from the Alzheimer’s field af­ter the many clin­i­cal im­plo­sions and dis­as­ters, Eli Lil­ly is still chug­ging along with its $2 bil­lion deal with AC Im­mune — de­spite its share of BACE woes. AC Im­mune is set to re­ceive its first mile­stone pay­ment of CHF30 mil­lion, al­most a year af­ter the deal was inked. The com­pa­ny said that the pay­ment “is a recog­ni­tion of progress in the col­lab­o­ra­tion be­tween the two com­pa­nies and fol­lows ini­ti­a­tion in Ju­ly 2019 of the Phase 1 study of ACI-3024, a first-in-class in­ves­ti­ga­tion­al oral small mol­e­cule Tau Mor­phomer in de­vel­op­ment for treat­ment of Alzheimer’s dis­ease (AD) and oth­er neu­rode­gen­er­a­tive dis­or­ders.” A sec­ond mile­stone pay­ment of the same amount is sched­uled for Q1 of 2020.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER